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Background: Roxithromycin (RXM) has been widely used in asthma treatment; however, the mechanism has not
been fully understood. The aim of our study was to investigate the underlying mechanism of RXM treatment in
mediating the effect of transforming growth factor (TGF)-β1 on airway smooth muscle cells (ASMCs) proliferation
and caveolinn-1 expression.
Methods: Firstly, the rat ovalbumin (OVA) model was built according to the previous papers. Rat ASMCs were prepared
and cultured, and then TGF-β1 production in ASMCs was measured by enzyme-linked immunosorbent assay (ELISA).
Moreover, the proliferation of ASMCs was determined using cell counting kit (CCK-8) assay. Additionally, the expressions
of caveolin-1, phosphorylated-ERK1/2 (p-ERK1/2) and phosphorylated–AKT (p-AKT) in ASMCs treated with or without
PD98059 (an ERK1/2 inhibitor), wortannin (a PI3K inhibitor), β-cyclodextrin (β-CD) and RXM were measured by Western
blot. Finally, data were evaluated using t–test or one-way ANOVA, and then a P value < 0.05 was set as a threshold.
Results: Compared with normal control, TGF-β1 secretion was significantly increased in asthmatic ASMCs; meanwhile,
TGF-β1 promoted ASMCs proliferation (P < 0.05). However, ASMCs proliferation was remarkably inhibited by RXM, β-CD,
PD98059 and wortmannin (P < 0.05). Moreover, the expressions of p-ERK1/2 and p-AKT were increased and peaked at
20 min after TGF-β1 stimulation, and then suppressed by RXM. Further, caveolin-1 level was down-regulated by TGF-β1
and up-regulated by inhibitors and RXM.
Conclusion: Our findings demonstrate that RXM treatment inhibits TGF-β1-induced activation of ERK and AKT and
down-regulation of caveolin-1, which may be the potential mechanism of RXM protection from chronic inflammatory
diseases, including bronchial asthma.
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Phosphatidylinositol 3-kinase/AKT pathwayIntroduction
With inflammation being the principle underlying patho-
physiological characteristic, asthma has been reported pri-
marily as an inflammatory disorder, which would drive
airway obstruction and remodeling [1]. Airway smooth
muscle (ASM) has been discovered plays a central role in
the pathogenesis of airway remodeling. Increased ASM* Correspondence: bai.chunxue@zs-hospital.sh.cn
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unless otherwise stated.mass has been shown to contribute to airway remodeling,
which results in persistent airflow limitation [2]. Despite
these studies have reported the potential pathogenesis of
airway remodeling, the underlying mechanisms are not
fully understood.
Previous studies have showed that transforming growth
factor-β1 (TGF-β1) is involved in the pathophysiology of
asthma [3]. Moreover, several researchers have discovered
that elevated TGF-β1 expression is seen in the airway sub-
mucosa of asthmatic individuals compared with normal
subjects; moreover, the TGF-β1 level is correlated with the
severity of the disease [4]. In addition, TGF-β1 has reported. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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production of extracellular matrix [6] in ASMCs, suggest-
ing a new mechanism of airway remodeling. But the effect
of TGF-β1 on the proliferation of ASMCs is still vague [7].
Roxithromycin (RXM), a fourteen-membered macro-
lide, enhances the phagocytic and bactericidal activities
of neutrophils [8]. Clinical studies have shown its effi-
cacy against chronic inflammatory diseases, including
diffuse panbronchiolitis [9], chronic sinusitis [10], atopic
dermatitis and bronchial asthma [11]. However, it is un-
clear if the beneficial effects are related to their anti-
microbial or anti-proliferation properties. RXM may play
an important role in TGFβ1-induced myofibroblast dif-
ferentiation and collagen production [12]. To determine
if RXM possesses anti-proliferation properties, the effect
of RXM on ASMCs proliferation was examined in our
present study; moreover, the potential mechanism of
RXM treatment for asthma was analyzed.
Caveolae are flask-shaped plasma membrane character-
ized by high hydrophobicity. Many signal molecules, in-
cluding caveolin-1, tyrosine kinase, Raf, MEK1/2, and
transient receptor potential canonical (TRPC) accumulate
in the caveolae [13]. Previous study has reported that
caveolin-1 preventing asthmatic ASMCs proliferation is
regulated by extracellular signal-regulated kinases 1 and 2
(ERK1/2) signal pathway, and then RXM reduces ASMCs
proliferation by up-regulating caveolin-1 expression [14].
Proliferation is controlled by many cellular signaling
pathways involving several serine/threoine kinase cas-
cades, including the phosphatidylinositol 3-kinase (PI3K)/
AKT and the mitogen-activated protein kinase (MAPK)
pathways. AKT, also known as protein kinase B, is a major
downstream target of PI3K activated in response to vari-
ous stimuli, growth factors, and hormones. Another key
mediator of growth is the ERK1/2. ERK1/2 belongs to the
MAPK family and locates downstream of the cascade of
Ras/Raf/MEK kinase. The nuclear translocation of ERK1/
2 is a critical step for cell growth. In phosphorylated and
activated forms, ERK1/2 transmits extracellular stimuli
form the plasma membrane to the nucleus by phosphoryl-
ating and activating a variety of transcription factors [15].
One published study has reported that inhibition of
ERK1/2 or PI3K/AKT signaling may attenuate ASM pro-
liferation [16]. Based on the above research results, our
study focused on investigating the mechanism of RXM
treatment for chronic inflammatory diseases.
In the present study, the role of RAM in TGF-β1-induced
activation of AKT and ERK1/2 and down-regulation of
caveolin-1 was explored. Firstly, the effect of TGF-β1 and
caveolin-1 on ASMCs proliferation was measured. Secondly,
the time course of TGF-β1-induced activation of ERK1/2
and AKT was examined. Finally, the mechanism of RXM
treatment in TGF-β1-induced ASMCs proliferation was an-
alyzed. Our study investigated the potential role of RXMtreatment in TGF-β1-induced asthma and analyzed the rela-
tionship between TGF-β1 and caveolin-1. This study set a
novel insight in the mechanism of RXM treatment which
may be helpful for chronic inflammatory diseases therapy.
Materials and methods
Materials and solutions
The recombinant human TGF-β1 was obtained from
Peprotech (Rocky Hill, NJ, USA). The following reagents
were purchased from Cell Signaling Technology Com-
pany (Boston, USA): rabbit anti-rat threonine/tyrosine
diphosphorylated ERK1/2 and total ERK1/2 antibodies,
MAPK inhibitor (PD98059), serine phosphorylated AKT,
AKT and PI3K inhibitor (wortannin). Rabbit anti-rat
caveolin-1 antibody was purchased from Abcam Company
(Cambridge, UK). RXM and β-cyclodextrin (β-CD) were
from Sigma Chemical Company (Santa Clara, CA, USA).
TGF-β1 and RXM were taken pure water and dimethyl
sulfoxide (DMSO) as their stock solutions, respectively.
The final DMSO concentration of less than 0.2% had no
significant effect on cells growth.
Animals and experimental protocol
Male Sprague–Dawley (SD) rats (200–250 g, 6 weeks old)
were purchased from SLAC Laboratory Animal Co., Ltd
(Shanghai, China) and divided into control and asthma
groups. The animals had no access to solid food but
gained free access to water 12 hours before the experi-
ments. The experimental protocol was approved by the
Committee of Animal Care in Wenzhou Medical Univer-
sity. All animals were handled in accordance with the
Guideline for the Care and Use of Laboratory Animals
[17]. The ovalbumin (OVA) model was constructed as
previously reported [18]: firstly, the rats were sensitized
with intraperitoneal injection of 10% OVA mixed with
10% alumin hydroxide solution, and then from day 15, the
rats were challenged for 30 min by an aerosol of 1% OVA
in normal saline, twice a week for 8 weeks. In control
group, OVA was replaced by saline during sensitization
and challenge. After the last challenge, 10% chloral hy-
drate was used for all animals’ euthanasia.
Preparation of ASMCS
ASMCs were isolated from male SD rats. Briefly, rat bron-
chi were isolated under sterile conditions. After the con-
nective tissue and epithelia were removed carefully, the
smooth muscle strips were cut into small pieces (<1 mm3)
and digested in phosphate buffer saline (PBS), containing
0.2% type I collagenase (Sigma, USA), at 37°C in a 5% CO2
and 95% air atmosphere for 20 min. The cells were dis-
persed and centrifuged at 1000 × g for 5 min, and then the
pellets were collected and resuspended in RPMI-1640,
containing 10% FBS and 1% penicillin-streptomycin. Fi-
nally, the cultures were maintained in a humidified
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were used for experiments. In each group, total six rats
were utilized and all experiments were repeated in cells
from the six different rats. For all experiments, cells
(5 × 105) were plated into tissue culture flasks or Petri
dishes and grown to 80% confluence. Furthermore, cells
were serum-deprived for 24 hours in RPMI-1640 (contain-
ing 0.5% FBS) prior to the addition of TGF-β1.
Stimuli and inhibitor
ASMCs were incubated in the low-serum medium with
or without TGF-β1 (10 ng/ml) for 48 h. The inhibitors,
including wortannin (a selective PI3K inhibitor) and
PD98059 (a selective ERK1/2 inhibitor), and β-CD which
could destroy caveolae (plasma membrane invaginations
that regulate a variety of physiological functions) were
used. Finally, 0.4 μM wortannin, 10 μM PD98059, and
10 mM β-CD were added to ASMCs 1 h prior to each
treatment according to manufacturers’ instructions.
Measurement of TGF-β1production
After centrifuged at 1500 × g for 5 min, ASMCs culture su-
pernatants were collected and stored at −80°C. The concen-
trations of TGF-β1 in the supernatants were determined
with a human TGF-β1 ELISA kit (Genzyme), according to
the manufacturers’ instructions. Assays were run in tripli-
cate and repeated twice.
CCK-8 proliferation assay
Cell proliferation was determined using a cell counting
kit (CCK-8, Beyotime Institute of Biotechnology, China),
according to the manufacturers’ instructions. Briefly, cells
were seeded at a density 5 × 103 cells/well on 96-well
plates and grown for the indicated time. After treatment,
10 μL of the CCK-8 solution was added into each well of
the plate, followed by incubation for 2 h. Then, cell prolif-
eration was determined by measuring absorbance at the
wavelength of 450 nm in four samples of each group.
Overall, total 9 groups, including control, asthma, TGF-
β1, wortannin, TGF-β1 + wortannin, PD98059, TGF-β1 +
PD98059, β-CD and TGF-β1 + β-CD, in this experiment.
Morphological observation and Western blot analysis
Scanning electron microscope (SEM) was used to show ca-
veolae structures and locations in ASMCs between control
and OVA group. In addition, during Western bolt analysis,
proteins were loaded onto each lane and separated by SDS-
PAGE (15% gradient gels, Criterion Gel System; Bio-Rad,
Hercules, CA), and then transferred onto polyvinylidene
difluoride membranes (Millipore, Billerica, MA 01821,
USA) for 30–60 min. After blocking with five percent non-
fat milk in TBS containing 0.1% Tween 20 (TBST) for 1 h,
membranes were incubated overnight at 4°C with primary
antibodies (rabbit anti-caveolin-1, 1:1000; rabbit anti-p-akt,1:1000; mouse anti-akt, 1:1000; rabbit anti-p-ERK1/2,
1:1000; mouse anti-ERK1/2, 1:1000; mouse anti-GAPDH,
1:5000). Following three washes with TBST, the membrane
was incubated with horseradish peroxidase (HRP)-conju-
gated secondary antibodies (1:2000) for 1 h at room
temperature and signals were developed by Gel Capture.
The time course of ERK and AKT activation
To determine the effect of TGF-β1 stimulation on activa-
tion of ERK and AKT, the expression of these proteins on
different time points (0, 5, 10, 15, and 60 min) were mea-
sured by Western blot. In detail, the expression of
phosphorylated-ERK1/2 (p-ERK1/2) and phosphorylated-
AKT (p-AKT) were assessed by Western blot and com-
pared to the levels of ERK1/2 and AKT, respectively.
The effect of RXM on p-ERK1/2, p-AKT and caveolin-1 levels
Cultured and serum-deprived asthmatic ASMCs were
treated with TGF-β1 for 20 min for p-ERK1/2 and p-AKT
measurement, with or without PD98059, wortmannin, β-
CD and RXM (100 μg/ml). The expressions of p-ERK1/2
and p-AKT were measured. In addition, asthmatic ASMCs
were treated with TGF-β1 for 48 h for caveolin-1 measure-
ment, with or without PD98059, wortmannin, β-CD and
RXM. Then the expression of caveolin-1 was detected.
Statistical analysis
Bronchial samples from six rats were used to obtain
ASMCs, with biochemistry and molecular biology protocols
being repeated at least three times. Data were evaluated by
t–test or one-way ANOVA for multiple comparisons. A P
value < 0.05 was considered significant. All data were
expressed as mean ± SD.
Results
TGF-β1 production in ASMCs and the effect of TGF-β1 on
ASMCs proliferation
To determine the secretion of TGF-β1 in rat ASMCs, cells
culture supernatants were collected and measured. Com-
pared with control group, the secretion of TGF-β1 in OVA
ASMCs was increased (P < 0.05, Figure 1A). Additionally,
TGF-β1 treatment was discovered significantly promoted
the proliferation of ASMCs (P < 0.05, Figure 1B). However,
wortannin, PD98059 and β-CD alone or combination with
TGF-β1 could inhibit the proliferation remarkably (P <
0.05). No significant difference was observed between
inhibitor groups and TGF-β1 combining with inhibitor
groups (Figure 1B).
Caveolae and caveolin-1 in ASMCs
By using SEM, we discovered that caveolae structures in
ASMCs between control and asthmatic group showed sig-
nificant differences. More caveolae were observed in con-
trol group than in asthmatic group (Figure 2A). Moreover,
Figure 1 TGF-β1 production in ASMCs and the effect of TGF-β1
on proliferation of ASMCs. (A) Supernatants were collected after
culture for 24 hours. Cytokine TGF-β1 was measured by ELISA. Data are
expressed as mean ± SD for each group. (*P < 0.05 versus control).
(B) Proliferation of ASMCs in each group was measure by CCK-8 assay.
Data are expressed as mean ± SD for each group. TGF-β1 significantly
promoted cell proliferation, which could be inhibited by PD98059,
wortmannin and β-CD (*P < 0.05 versus control and asthma group,
#P < 0.05 versus control group, **P < 0.05 versus TGF-β1 group). No
significant change between inhibitor group and TGF-β1 + inhibitor
group was observed.
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expressed in ASMCs. Compared with control group, the
expression of caveolin-1 was significantly decreased in
asthmatic group (P < 0.05, Figure 2B).
The time course of ERK and AKT activation in ASMCs
stimulated with TGF-β1
The effect of TGF-β1 on activation and expression of ERK
and AKT was measured and our results indicated that
ASMCs had a low level of p-ERK1/2 at the beginning ofTGF-β1 stimulation. Over time, activation of ERK path-
way reached to almost twofold of time zero at 20 min (P <
0.05), and then the level lowered and sustained at 60 min
(Figure 3A, C). While, activation of AKT pathway reached
its peak at 20 min and nearly maintained at the peak level
at 60 min (Figure 3B, D).
Mechanisms of TGF-β1-induced reduction in caveolin-1
and the effect of altered caveolin-1 expression on PI3K/
AKT and ERK1/2 regulation
Western blot analysis of ASMCs demonstrated a signifi-
cantly reduced expression of caveolin-1 with TGF-β1 ex-
posure (P < 0.05), and then caveolin-1 level was increased
slightly after treated with either 10 μM PD98059 (ERK1/2
inhibitor) or 0.4 μM wortmannin (PI3K/AKT inhibitor)
(Figure 4A, C, E, G). This result indicated that TGF-β1
inhibited caveolin-1 expression partly through PI3K and
ERK1/2 pathways. In addition, the caveolae in cultured
ASMCs were destroyed by β-CD with the expression of
activated p-AKT and p-ERK1/2 significantly increased
(P < 0.05), followed by decreased expression of caveolin-1
(P < 0.05) (Figure 4B, D, F, H). According to our results, de-
creased caveolin-1 expression was downstream of ERK and
AKT activation. Thus, inhibition of ERK and AKT would
inhibit TGF-β1-induced down-regulation of Caveolin-1.
The effect of RXM on AKT and ERK1/2 activation and
caveolin-1 expression
The effect of RXM on caveolin-1 expression in ASMCs was
assessed by western blot. Compared with TGF-β1 group,
RXM significantly increased the expression of caveolin-1
protein (P < 0.05) (Figure 4A, C, E, G). In addition, the ex-
pressions of p-AKT and p-ERK1/2 were significantly stimu-
lated by TGF-β1 in ASMCs (P < 0.05), and remarkably
down-regulated by RXM (P < 0.05) (Figure 4B, D, F, H). In a
word, RXM treatment inhibited TGF-β1-induced activation
of AKTand ERK1/2 and down-regulation of caveolin-1.
Discussion
Our present study indicates that RXM treatment inhibits
TGF-β1-induced activation of ERK and AKT and down-
regulation of Caveolin-1 in ASMCs, which is an interest-
ing novel finding about the potential mechanisms of
RXM protection from chronic inflammatory diseases, in-
cluding bronchial asthma seen in clinical studies. TGF-
β1 is a central mediator in tissue remodeling processes,
including fibrosis and ASM hyperplasia, as observed in
asthma [19]. In our study, TGF-β1 secretion in ASMCs
from OVA rats was increased, which promoted ASMCs
themselves proliferation significantly. Different mecha-
nisms have been suggested to explain the role of TGF-
β1 in ASMCs proliferation. While, our present study
found TGF-β1 reduced caveolin-1 expression on plasma
membrane and promoted its partial translocation to the
Figure 2 The presence of caveolae and caveolin-1 in ASMCs. (A) Normal caveolae structures were observed in the control group by
scanning electron microscope (×7000). All the scale bars are 2 μm. However, there were fewer caveolae structures observed in the asthma group
compared with control group. The locations of caveolae were indicated with arrows. (B) Western blot was used for analysis of caveolin-1 in separate
group. GAPDH served as a loading control. The expression of caveolin-1 protein was significantly decreased in the asthma group. Data are expressed as
mean ± SD for each group. (*P < 0.05 versus control).
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would unlock a negative regulation process which allows
TGF-β1 to promote ASMCs proliferation. This may be
the new mechanism about TGF-β1 affecting ASMCs
biological processes.
Caveolae are flask-shaped plasma membrane invagina-
tions rich in cholesterol and sphingolipids. They express
any of three caveolin proteins (caveolin-1, caveolin-2, and/
or caveolin-3) and contain agonist receptors, ion channels,
and other membrane proteins [20]. Caveolin-1 is a main
component of caveolae. Studies using gene knockout tech-
nology indicate that caveolin-1 plays a key role in the for-
mation and mobility of the caveolae [21]. In our present
study, caveolae and caveolin-1 were few in asthmatic
ASMCs, while they were abundant in normal cells. Ab-
sence of caveolin-1, an essential protein for caveolae for-
mation on the plasma membrane, abrogated TGF-β1
mediated phosphorylation of AKT, which culminated in
decreased ASMCs proliferation. In addition, recent studies
have proposed that TGF-β mediates AKT activation is fa-
cilitated via EGFR (epidermal growth factor receptor) lig-
and secretion, EGFR activation and subsequent c-Src
phosphorylation [22,23]. However, caveolin-1 was shown
to counteract EGFR signaling [24,25]. Additionally, PI3K/AKT signaling has recently been shown to require lipid
raft compartments (where caveolin-1 is usually located) to
enable activation [26]. Our further research activities will
shed insight on how TGF-β induces AKT in a caveolin-1
dependent manner.
Other papers have shown that caveolae structures are
required for ERK1/2 activation and ERK1/2 activation is
decreased after the caveolae structure is destroyed by
removing cholesterol from the plasma membrane using β-
CD, which in turn inhibits cell proliferation [27,28]. Fur-
thermore, studies using cholesterol to increase ERK1/2
activation resulted in an increase in cell proliferation.
These findings suggest that caveolae collect ERK1/2
and other signal molecules resulting in the activation
of phosphorylated cascade of ERK1/2, indicating that
caveolae might be pivotal for the generation of signal-
ing mechanisms that trigger cell proliferation. In our
study, β-CD was discovered inhibited TGF-β1-induced
ASMCs proliferation and decreased p-ERK1/2 and p-
AKT expression, suggesting that an intact caveolae
were required for TGF-β1-induced ASMCs prolifera-
tion, ERK1/2 and AKT activation.
In ASMCs, following TGF-β1 stimulation, both PI3K/
AKT and ERK1/2 pathways were activated independently
Figure 3 The time course of ERK and AKT activation in ASMCs stimulated with TGF-β1. (A, C) Asthmatic ASMCs were incubated with TGF-β1
(10 ng/ml) for 5, 10, 15, 20 and 60 min. The expression of p-ERK1/2 protein was assessed by western blot and analyzed by densitometry compared to
ERK1/2 expression. The expression of p-ERK1/2 protein in ASMCs was increased and peaked at 20 min after TGF-β1 stimulation (*P < 0.05 versus control,
5, 10, 15, 60 min groups). (B, D) Asthmatic ASMCs were incubated with TGF-β1 (10 ng/ml) for 5, 10, 15, 20, and 60 min. The expression of p-AKT protein
was assessed by western blot and analyzed by densitometry compared to AKT expression. The expression of p-AKT protein in ASMCs was increased
and peaked at 20 min after TGF-β1 stimulation (*P < 0.05 versus control, 5, 10, 15, 60 min groups).
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an enhanced Raf/MEK/ERK effect upon PI3K/AKT activa-
tion [29,30]. The stimulation of both pathways by many
common ligands raises the possibility that cross-talking
between the PI3K/AKT and ERK1/2 pathways could play
a major role in regulating cell proliferation under particu-
lar conditions. Cross-talking between PI3K/AKT and Ras/
Raf/MEK/ERK1/2 occurs at different levels and exerts co-
operative or antagonistic effects depending on external
stimuli and cellular background. Cooperative effects
between these two signaling cascades have also been dem-
onstrated in the regulation of platelet-derived growth
factor-induced proliferation. In our study, exposure of
ASMCs to TGF-β1 resulted in PI3K/AKT and ERK1/2
pathways activation with similar time course. To date, the
molecular mechanisms and functional cellular conse-
quences of this cross-talking remain poorly investigated.
Interestingly, our results also suggest that RXM sup-
presses ASMCs proliferation stimulated with TGF-β1 and
caveolin-1 down-expression induced by TGF-β1. The
present study reveals that RXM inhibits activation of PI3K/
AKTand ERK1/2 pathways. Sohshi et al. have reported that
RXM has the ability to inhibit phosphorylation of AKT and
ERK of EL-4 cells [31]. Zeng et al. discover that RXM sup-
presses asthmatic ASMCs through up-regulating caveolin-1
expression and inhibiting monocyte chemotactic protein-1
expression [14]. In addition, RXM has the ability to inhibitTNF-α-mediated matrix metalloproteinase (MMP)-1 in-
duction through ERK1/2 down-regulation, and then treats
MMP-1 induced chronic inflammation diseases [32]. On
the other hand, it has shown that RXM has an effect on
the cyclin-dependent kinases (CDKs) activities and the ex-
pression of cell cycle regulatory proteins. RXM could
clearly suppress both CDK4 and CDK2 activities without
affecting their protein levels. The reduction of CDK4 and
CDK2 activities is likely due to the decreased expression
of cyclin D1 and cyclin A, and inhibition of p27 down-
regulation. Moreover, RXM inhibits human coronary ar-
tery smooth muscle cells (CASMCs) proliferation by
modulating cell cycle regulatory proteins and suppressing
NF-kappaB signaling pathway [33]. Overall, our findings
are consistent with these previous studies and reveal a
novel mechanism of RXM treatment for chronic inflam-
mation disease, including asthma.
Conclusion
In conclusion, the results of the present study demon-
strate that RXM treatment inhibits TGF-β1-induced
ASMCs proliferation which may suppress activation of
PI3K/AKT and ERK1/2 activation and caveolin-1 down-
expression. This anti-proliferative effect of RXM would
propose a novel beneficial mechanism in clinical trials
using antibiotics. In next study, we plan to explore the
role of RXM in TGF-β1 or caveolin-1 expression and
Figure 4 Caveolin-1 suppressed expression of phosphorylated PI3K and ERK1/2 in ASMCs. Cultured and serum-deprived ASMCs were
treated with TGF-β1 for 20 min for p-ERK1/2 (B, D) and for p-AKT (F, H) measurement, with or without preincubation with PD98059, wortmannin,
β-CD and RXM. The expressions of p-ERK1/2 and p-AKT were up-regulated by TGF-β1 and significantly down-regulated by PD98059, wortmannin,
β-CD and RXM. (A, C, E, G) Asthmatic ASMCs were treated with TGF-β1 for 48 h for caveolin-1 measurement, with or without preincubation with
PD98059, wortmannin, β-CD and RXM. The expression of caveolin-1 was down-regulated by TGF-β1and up-regulated by PD98059, wortmannin
and RXM. Data are expressed as mean ± SD for each group (*P < 0.05 versus asthma and control group, & P < 0.05 versus control group, #P < 0.05
versus TGF-β1 group).
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TGF-β1 and caveolin-1 will be examined by either im-
munostaining or hybridization in our next experiment.Additionally, caveolin-1 siRNA or TGF-β1 receptor in-
hibition will be used to address the underlying signaling
mechanisms in our plan.
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